Marc L. Berger, MD

Articles by Marc L. Berger, MD

GRACE Principles: Recognizing High-Quality Observational Studies of Comparative Effectiveness

ByNancy A. Dreyer, PhD,Sebastian Schneeweiss, MD,Barbara J. McNeil, MD,Marc L. Berger, MD,Alec M. Walker, MD,Daniel A. Ollendorf, MPH,Richard E. Gliklich, MD,for the GRACE Initiative

June 4th 2010

The GRACE principles lay out 3 questions to help healthcare providers, patients, and other decision makers evaluate the quality of noninterventional comparative effectiveness studies.

Do Drug Formulary Policies Reflect Evidence of Value?

ByPeter J. Neumann, ScD,Pei-Jung Lin, MS,Dan Greenberg, PhD,Marc L. Berger, MD,Steven M. Teutsch, MD,Edward Mansley, PhD,Milton C. Weinstein, PhD,Allison B. Rosen, MD, ScD

January 1st 2006

Impact of 3-Tier Pharmacy Benefit Design and Increased Consumer Cost-sharing on Drug Utilization

ByPamela B. Landsman, MPH, DrPH,Winnie Yu, PharmD,XiaoFeng Liu, PhD,Steven M. Teutsch, MD,Marc L. Berger, MD

October 1st 2005

Indirect Cost of Ischemic Heart Disease to Employers

ByBruce Sherman, MD. Author Reply by Christine J. Guico-Pabia, MD, MBA,James F. Murray, PhD,Marc L. Berger, MD,Steven M. Teutsch, MD, MPH

April 1st 2001

Indirect Cost of Ischemic Heart Disease to Employers

ByChristine J. Guico-Pabia, MD, MBA,James F. Murray, PhD,Steven M. Teutsch, MD, MPH,Albert I. Wertheimer, PhD, MBA,Marc L. Berger, MD

January 1st 2001

The Cholesterol Population Model: US Population Requirements for Treatment of Hypercholesterolemia

ByRobert S. Epstein, MD, MS,Susan Garrahan,Linda Nelsen, MS,Pamela Laber,Eve Slater, MD,Marc L. Berger, MD

December 1st 1996

Latest Updated Articles

Do Drug Formulary Policies Reflect Evidence of Value?
Published: January 1st 2006 | Updated:
Indirect Cost of Ischemic Heart Disease to Employers
Published: January 1st 2001 | Updated:
The Cholesterol Population Model: US Population Requirements for Treatment of Hypercholesterolemia
Published: December 1st 1996 | Updated:
Indirect Cost of Ischemic Heart Disease to Employers
Published: April 1st 2001 | Updated:
GRACE Principles: Recognizing High-Quality Observational Studies of Comparative Effectiveness
Published: June 4th 2010 | Updated:
Impact of 3-Tier Pharmacy Benefit Design and Increased Consumer Cost-sharing on Drug Utilization
Published: October 1st 2005 | Updated:

Marc L. Berger, MD

Articles by Marc L. Berger, MD

GRACE Principles: Recognizing High-Quality Observational Studies of Comparative Effectiveness

Do Drug Formulary Policies Reflect Evidence of Value?

Impact of 3-Tier Pharmacy Benefit Design and Increased Consumer Cost-sharing on Drug Utilization

Indirect Cost of Ischemic Heart Disease to Employers

Indirect Cost of Ischemic Heart Disease to Employers

The Cholesterol Population Model: US Population Requirements for Treatment of Hypercholesterolemia

Latest Updated Articles

Trending on AJMC

Physical Activity, Vaccination May Protect Against Long COVID

Real-World Data Show Preventive Nirsevimab Reduces Infant RSV Hospitalizations

Medicare State Rankings Reveal Stark Differences in Access, Quality, and Affordability

In Its 50th Year, ESMO Comes to Berlin, a City Transformed

First-Line Zongertinib Yields Strong Responses in Patients With Advanced HER2-Mutant NSCLC